- €2.1 billion will be invested starting in 2023 to expand the Chartres site.
- The expansion will be completed between 2026 and 2028.
- The project will create over 500 new jobs and employ up to 2,000 external workers during construction.
- The facility will include capacity for GLP-1 products.
Investment Overview
Novo Nordisk is investing over €2.1 billion, starting in 2023, to expand its production site in Chartres, France. This investment aims to enhance the manufacturing capacity for current and future products targeting serious chronic diseases.
Expansion Details
The expansion will significantly increase the site's capacity, adding aseptic production and finished production processes, as well as extending the current Quality Control Laboratory. The new facilities will more than double the site's footprint and will be designed as a multi-product facility to accommodate various processes with state-of-the-art technology.
Timeline and Job Creation
Construction projects have already begun and will be gradually completed from 2026 to 2028. The investment is expected to create over 500 new jobs for running production activities around the clock once the construction is finished. During the construction phase, up to 2,000 external employees will be employed.
Environmental Sustainability
The new facilities will focus on delivering high-quality products in an efficient and environmentally sustainable manner, including a 25% reduction in water consumption compared to current production lines.
